Varian gains more worldwide sites for RapidArc system

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

The Potential for Improved Processes, Outcomes, and Economics of Health Care

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Nora Janjan, MD, MPSA, MBA

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

February 10th 2025

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Roman Fabbricatore

February 20th 2025

Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

February 20th 2025

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Related Content

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

The Potential for Improved Processes, Outcomes, and Economics of Health Care

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Nora Janjan, MD, MPSA, MBA

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP

February 10th 2025

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Roman Fabbricatore

February 20th 2025

Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.